clinical trial · NCT05147792
The CONFORM Pivotal Trial
Conformal Medical, Inc·N/A·recruiting·n = 1,600
Atrial FibrillationStrokeCLAASWATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder
brief summary
The CLAAS® device will be evaluated for safety and efficacy by establishing its performance is non-inferior to the commercially available WATCHMAN® and Amulet™ left atrial appendage closure devices in patients with non-valvular atrial fibrillation. Patients who are eligible for the trial will be randomized to receive either the CLAAS device or the WATCHMAN or Amulet™ devices and will be followed for 5 years after device implant.
started
May 26, 2022
primary completion
Jun 1, 2028
completion
Dec 1, 2031
last updated
Mar 18, 2026
official title
An Evaluation of the Safety and Effectiveness of the Conformal CLAAS System for Left Atrial Appendage Occlusion
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol